Author:
Dovio A.,Generali D.,Tampellini M.,Berruti A.,Tedoldi S.,Torta M.,Bonardi S.,Tucci M.,Allevi G.,Aguggini S.,Bottini A.,Dogliotti L.,Angeli A.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference29 articles.
1. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495
2. Theoleyre S, Wittrant Y, Tat SK, et al (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457–475
3. Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331
4. Dovio A, Data V, Angeli A (2005) Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 28 [10 Suppl]:14–22
5. Camacho P, Kleerekoper M (2006) Biochemical markers of bone turnover. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. The American Society for Bone and Mineral Research, Washington, DC, pp 127–132
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献